PR86062

PARIS, MONTREAL and QUEBEC CITY, Oct. 13, 2020 /PRNewswire=KYODO JBN/ --

Strategic partnership in brain imaging and AI

- Acquisition of TRUE POSITIVE MEDICAL DEVICES by QYNAPSE

- A strategic collaboration that covers 15 patents, including 9 issued in the

U.S. and Canada

- A unique technology alliance to improve clinical trials performance and

personalize brain diseases management

QYNAPSE SAS[http://www.qynapse.com/], a French medical technology company,

today announces the acquisition of the Canadian company TRUE POSITIVE MEDICAL

DEVICES Inc.[http://www.truepositivemd.com/] (TPMD), a spin-off from the

universities of McGill and Laval. The objective of this strategic collaboration

is to combine TPMD's technologies, patents and expertise with Qynapse's

know-how and product line – and thus form the most advanced artificial

intelligence (AI) platform in the field of imaging of brain diseases such as

Alzheimer's, Parkinson's and multiple sclerosis.

Over the past fifteen years, the founders of TPMD, Prof. Louis Collins (McGill

University, Montreal, Canada) and Prof. Simon Duchesne (Université Laval,

Quebec City, Canada) have established one of the most impressive scientific and

technological asset bases in brain imaging and AI applied to this field,

supported by more than 500 publications and scientific communications. These

technologies are already being used in Canada by leading research consortia and

private international players in studies specifically related to

neurodegeneration, such as Alzheimer's disease.

QYNAPSE is already marketing its first

QyScore(R)[http://www.qynapse.com/qyscore-software/] medical device to clinical

centers in Europe and the United States. Its platform is also used in clinical

trials involving dozens of centers worldwide. The collaboration with TPMD will

allow QYNAPSE to extend the applications of its QyScore(R) software to other

brain diseases such as stroke, epilepsy, autism, schizophrenia, and head trauma

– and also to develop new software to predict clinical progression for

individual patients and optimize enrollment in clinical trials.

QYNAPSE's acquisition of TPMD covers 15 patents, including 9 issued in the

United States and Canada, grouped into nine technological asset families. The

founders of TPMD will join QYNAPSE's scientific board, setting the stage for a

long-term collaboration.

According to Prof. Louis Collins: "QYNAPSE is a very promising partner for TPMD

and both McGill and Laval universities, which will allow us to accelerate the

regulatory approval and marketing of the technologies we have developed in

recent years". Prof. Duchesne adds, "Indeed, with QYNAPSE we will have access

to a partner that is already well established in the medical field. We look

forward to providing clinicians with the tools they need to improve the

accuracy of their diagnosis, facilitate prognosis and guide treatment for

diseases such as dementias and cerebrovascular diseases."

"We are delighted to partner with two of the world's leading experts in brain

imaging, and to expand our scientific and clinical collaborations with two

major centers of excellence in this field." said Olivier Courrèges, CEO of

QYNAPSE. "This collaboration will create a unique technological structure,

strengthening our ability to deploy powerful tools to address two major

challenges: clinical trial performance and personalized management of brain

diseases, which affect more than one in six people worldwide."

Once finalized, TPMD will be integrated into QYNAPSE CANADA Inc. and TPMD's

scientific and commercial partnership contracts will be operated by this new

entity.

About QYNAPSE

Founded in 2015, QYNAPSE is a French medical technology company, a spin-off

from the CATI consortium of neuroimaging research laboratories. The company

develops and markets solutions utilizing the potential of quantitative imaging

and artificial intelligence to optimize diagnosis, prognosis and monitoring of

patients with neurological diseases.

QYNAPSE is headquartered in Paris (France) and in Boston (USA).

www.qynapse.com

www.qynapse.com/qyscore-software/

About TRUE POSITIVE MEDICAL DEVICES (TPMD)

Founded in 2011, TRUE POSITIVE MEDICAL DEVICE Inc. is a spin-off from the work

of Prof. Simon Duchesne at the CERVO Brain Research Center and Université Laval

and Prof. Louis Collins at the Montreal Neurological Institute and McGill

University. The company designs, validates and operates a brain image

processing platform to aid in the diagnosis and prognosis of neurological and

psychiatric diseases.

TPMD is based in Montreal and Quebec City (QC, Canada).

www.truepositivemd.com  

Logo - https://mma.prnewswire.com/media/1311169/Qynapse_Logo.jpg

Photo - https://mma.prnewswire.com/media/1311170/QyScore_application.jpg

Media Contact

Ysé Sallé de Chou

Qynapse

ysalledechou@qynapse.com

Source: QYNAPSE